Recommends discontinuation of GLP-1RA before conception rather than between start of pregnancy and end of first trimester for individuals with type 2 diabetes who are planning pregnancy. Trigger when clinician considers stopping GLP-1RA therapy in a patient with type 2 diabetes who is planning pregnancy or seeking preconception care.
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill pdm-glp1ra-discontinuation-timing --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Pdm Glp1ra Discontinuation Timing?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-pdm-glp1ra-discontinuation-timing)More formats (shields.io, HTML) on the badges page.
---
name: pdm-glp1ra-discontinuation-timing
description: Recommends discontinuation of GLP-1RA before conception rather than between start of pregnancy and end of first trimester for individuals with type 2 diabetes who are planning pregnancy. Trigger when clinician considers stopping GLP-1RA therapy in a patient with type 2 diabetes who is planning pregnancy or seeking preconception care.
---
# Discontinue GLP-1RA before conception in type 2 diabetes
## STEP 1 — Gather Information
Collect pregnancy intention, current GLP-1RA regimen and dosing, contraception method, HbA1c, weight, renal function, and anticipated timing of conception after contraception cessation.
## STEP 2 — Rule In / Rule Out
Rule in: patient with type 2 diabetes mellitus currently on a GLP-1RA who is planning pregnancy or seeking preconception care; rule out: patient not planning pregnancy, already pregnant, has type 1 diabetes, or is not on a GLP-1RA.
## STEP 3 — Classify or Stratify
Stratify by anticipated conception timing (<1 month, 1–3 months, >3 months) and GLP-1RA half‑life (short‑acting e.g., lixisenatide vs long‑acting e.g., semaglutide) to determine discontinuation window and need for insulin transition.
## STEP 4 — Decide
Discontinue GLP-1RA at least 1 month before desired conception for short‑acting agents and 2 months for long‑acting agents; initiate insulin or other pregnancy‑safe antihyperglycemic agent; maintain effective contraception until conception is desired; optimize glycemia to HbA1c <6.5% before conception attempt.
## Clinical Guardrails / Mimics / Pitfalls
Do not discontinue GLP-1RA without ensuring effective contraception to avoid hyperglycemia‑related teratogenicity; avoid abrupt cessation leading to weight gain and hyperglycemia; do not delay discontinuation until after pregnancy confirmation; do not neglect active glycemic management after GLP-1RA stop; do not overlook risks of prolonged time off GLP-1RA such as rebound weight gain.
## Concrete Clinical Example
A 32‑year‑old woman with type 2 diabetes on semaglutide 1 mg weekly desires pregnancy in the next 3 months and uses condoms. Advise to stop semaglutide now, start basal‑bolus insulin titrated to fasting <95 mg/dL, continue contraception for another month to allow washout, then attempt conception after confirming HbA1c <6.5% and stable weight.
**Source:** Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline, Endocrine Society, 2025, https://doi.org/10.1210/clinem/dgaf288
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!